验证码已发送至您的邮箱或手机，请查收。
Phase II Active
Research Code CaCP-29; IFX-1
CAS No.
(Alferon, Naturaferon®) Approved
An interferon α-n3 potentially for the treatment of human papillomavirus infections.
Research Code
CAS No.
99210-65-8
Research Code NGM-313
CAS No.
Research Code aCD-3; aCD-3-MAb;OKT-3-oral-NasVax; Oral-anti-CD3-MAb; TRX-318
CAS No.
Follitropin alfa biosimilar (Allergan/Itero Biopharmaceuticals)
Phase III Active
A recombinant follicle stimulating hormone potentially for the treatment of female infertility.
Research Code
CAS No.
146479-72-3 (Follitropin alfa)
Research Code PRX-003
CAS No.
Phase II Discontinued
A calcium channel antagonist potentially for the treatment of angina pectoris and hypertension.
Research Code YS-201
CAS No.
108852-42-2(YS-201)
Research Code AB-16B5; 16B5; AB-sCLU mAB
CAS No.
Phase I Active
A programmed death receptor-1 (PD-1) blocker potentially for the treatment of colorectal cancer.
Research Code 2661380; AMP-244; GSK-2661380
CAS No.
Research Code DLBS-2411
CAS No.
Polyadenylic polyuridylic acid
NDA Filing Pending
An immunostimulant potentially for the treatment of breast cancer.
Research Code BN-52101
CAS No.
Factor IX long-acting (OPKO Health)
Phase I Pending
A long-acting factor IX potentially for the treatment of haemophilia B.
Research Code Factor IX-CTP; FIX-CTP; MOD-9017
CAS No.
Phase II Active
A long-acting factor VIIa-CTP fusion protein potentially for the treatment of haemophilia.
Research Code MOD-5014; MOD-5017
CAS No.
Recombinant lactoferrin (Ventria Bioscience)
Phase II Active
A recombinant human lactoferrin potentially for the treatment of inflammation.
Research Code VEN-100; VEN-101; VEN-120; VEN-130; VEN-140; VEN-150
CAS No.
Recombinant human ErbB3 fragment vaccine (Zensun)
Phase I Active
A vaccine potentially for the treatment of cancer.
Research Code rhErbB3-f
CAS No.
Recombinant human neuregulin-1
(Neucardin®) Active
A recombinant human neuregulin-1 β potentially for the treatment of chronic heart failure.
Research Code rhNRG-1
CAS No.
Dornase alfa biobetter (Pharmsynthez/Xenetic Biosciences)
(PulmoXen, Bronchozym®) Phase I Active
A recombinant DNase enzyme potentially for the treatment of cystic fibrosis.
Research Code PSA-DNase
CAS No.
9003-98-9(Traditional dornase alfa)
(Camedon; Cycloferon; Kamedon; Neovir; Virexxa®) Phase II Active
A progesterone receptor (PR) modulator potentially for the treatment of endometrial cancer.
Research Code
CAS No.
58880-43-6(Cridanimod sodium)
38609-97-1(Cridanimod)
An interferon α-n3 potentially for the treatment of human papillomavirus infections.
A progesterone receptor (PR) modulator potentially for the treatment of endometrial cancer.
Successful modification
Please choose to cancel the drug
